Competing risks analysis hazard ratios and level of significance for hazard ratios of prognostic factors for all cause mortality, all cardiovascular mortality, sudden death, and chronic heart failure death
| Hazard ratio | |||||
|---|---|---|---|---|---|
| Prognostic factor | All cause mortality (H=666, L=717) | All cardiovascular mortality (H=583, L=641) | CHF death (H=203, L=242) | Sudden death (H=286, L=303) | Out of hospital death (H=285, L=322) |
| *Represents a significant hazard ratio (1:0) at p < 0.05. | |||||
| **Represents a significant hazard ratio (1:0) at p < 0.001. | |||||
| ***Represents a significant hazard ratio (1:0) at p < 0.0001. | |||||
| †Antiarrhythmic drugs were received by 9.7% of patients at randomisation and included amiodarone (93% of patients receiving antiarrhythmics), aprindine, bretylium tosilate, disopyramide, flecainide, propafenone, and tocainide. | |||||
| ACE, angiotensin converting enzyme; BP, blood pressure; CHF, chronic heart failure; H, high dose lisinopril; L, low dose lisinopril; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association. | |||||
| Lisinopril treatment (high: low) | 0.923 | 0.903 | 0.827 | 0.922 | 0.879 |
| Demographics | |||||
| Age (years) – continuous | 1.025*** | 1.022*** | 1.029*** | 1.012** | 1.019*** |
| Sex (male: female) | 1.164* | 1.156 | 1.095 | 1.232 | 1.349* |
| Ischaemic heart disease (yes/no) | 1.315*** | 1.393*** | 1.466** | 1.251* | 1.214 |
| Haemodynamics | |||||
| LVEF (%) – continuous | 0.973*** | 0.969*** | 0.960*** | 0.970*** | 0.974*** |
| NYHA (III + IV : II) | 1.106 | 1.110 | 1.301 | 1.046 | 0.982 |
| Systolic BP (mm Hg) – continuous | 0.996* | 0.995* | 0.989** | 0.998 | 0.997 |
| Diastolic BP (mm Hg) – continuous | 0.995 | 0.997 | 0.989 | 0.999 | 1.000 |
| Heart rate (beats/min) – continuous | 1.011*** | 1.012*** | 1.025*** | 1.000 | 1.006 |
| Laboratory values | |||||
| Sodium (mmol/l) – continuous | 0.987 | 0.987 | 0.974* | 0.994 | 1.002 |
| Potassium (mmol/l) – continuous | 0.923 | 0.910 | 1.009 | 0.865 | 0.933 |
| Creatinine (μmol/l) – continuous | 1.005*** | 1.004*** | 1.006*** | 1.003* | 1.004** |
| Haemoglobin (g/l) – continuous | 0.983 | 0.999 | 0.927* | 1.036 | 0.983 |
| Drugs at randomisation | |||||
| Antidiabetic (yes 611: no 2553) | 1.093 | 1.101 | 1.180 | 1.143 | 1.137 |
| Aspirin (yes 1278: no 1886) | 0.825** | 0.859* | 0.704** | 1.031 | 0.975 |
| β Blockers (yes 353: no 2811) | 0.792* | 0.769* | 0.781 | 0.714* | 0.637** |
| Long acting nitrates (yes 786: no 2378) | 1.241*** | 1.289*** | 1.165 | 1.351** | 1.283** |
| Short acting nitrates (yes 726: no 2438) | 1.087 | 1.120 | 1.171 | 1.158 | 1.026 |
| Previous ACE inhibitor (yes 2810: no 354) | 1.271** | 1.310** | 1.369 | 1.337* | 1.176 |
| Antiarrhythmics (yes 306: no 2858)† | 1.010 | 1.018 | 1.457* | 0.703* | 0.627** |
| Calcium channel blockers (yes 369: no 2795) | 1.027 | 0.986 | 0.875 | 0.984 | 1.109 |
| Anticoagulants/warfarin (yes 1126: no 2038) | 0.999 | 1.040 | 0.978 | 1.187 | 1.107 |